Dr. ZHU Zhongyuan, is the founder, chairman of the Board, executive Director and chief executive officer of our Company. He also holds directorships and managerial positions across our subsidiaries. Dr. ZHU was re-designated as our executive Director on August 12, 2024. He is primarily responsible for strategic vision, corporate management and business planning of our Group.

Dr. ZHU is a sophisticated and resourceful veteran in China’s biotech industry with strong scientific and business acumen. He brings in over 20 years of experience bridging the realms of biotech entrepreneurship and venture investment. Dr. ZHU has been instrumental in investing in and incubating a number of notable emerging biotech companies, including CStone Pharmaceuticals (2616.HK), RemeGen (9995.HK), Gan & Lee Pharmaceuticals (603087. SH), and BGI Genomics (300676. SH). Throughout his career, Dr. ZHU has focused on value creation, and has established a reputation of driving growth and innovation, navigating marketdynamics while managing operational risks. He developed company building acumen at two leading biotech venture investment firms, including 6 Dimensions Capital, where he served as a Partner from 2018 to 2019, and Wuxi Healthcare Ventures, where he also held the position of Partner from 2015 to 2017. Prior to these roles, Dr. ZHU held various senior roles at Mingxin Capital, SIG Asia Investment Fund, Greenwoods Investment and HighLight Capital, from 2008 to 2015.

In addition, Dr. ZHU held multiple non-executive directorships at various portfolio companies, including a non-executive director of Phoenix Healthcare Group Co., Ltd. (currently known as China Resources Medical Holdings Company Limited (1515. HK)), from September 2013 to July 2014, and a non-executive director of CStone Pharmaceuticals (2616. HK), from April 2016 to August 2018. In 2006, he was the senior director at Shanghai Genomics, Inc., which was later acquired by GNI Group Ltd, an integrated multinational biopharma.

Dr. ZHU obtained a bachelor’s degree in molecular biology from Nankai University in the PRC in July 1992, a Ph.D. in biomedical science from the University of Massachusetts at Worcester in the United States in June 2001, and an MBA from the University of California at Berkeley in the United States in December 2005. In July 2020, Dr. ZHU was honored with “14th Jinji Lake Leading Scientific Talent of Suzhou Industrial Park” by the Suzhou Industrial Park Administrative Committee .

Mr. ZHANG Shaoren, is our executive Director and vice president of finance. Mr. ZHANG has been our Director since April 23, 2021, and re-designated as our executive Director on August 12, 2024. He is primarily responsible for the overall financial strategy, corporate finance, capital management and investor relations of our Group. Mr. ZHANG served as various senior positions within our Group previously, including a director from May 2020 to July 2021, and an executive director from August 2021 to February 2024.

Mr. ZHANG’s extensive financial management, strategic investment, and financing experience spans over 15 years. He honed his expertise during his tenure as manager at PricewaterhouseCoopers Zhong Tian LLP from September 2008 to November 2015, with his last position as manager at the audit department where he was primarily responsible for providing audit services to multiple clients. From December 2015 to June 2017, Mr. ZHANG served as the deputy general manager for Shanghai Yikang Medical Laboratory Co., Ltd. , a company dedicated to the R&D of single-cell whole genome amplification and sequencing technology for the field of eugenics and early cancer diagnosis, responsible for overseeing financial and operational management. From February 2017 to December 2019, Mr. ZHANG served as the deputy general manager of Shanghai Shihao International Logistics Co., Ltd. , a logistics service company and an affiliate of Y.U.D. Yangtze River Investment Industry Co., Ltd. , a comprehensive logistics company listed on Shanghai Stock Exchange (stock code: 600119), where he was responsible for the company’s overall operations.

Mr. ZHANG obtained a bachelor’s degree in international accounting from Shanghai Institute of Foreign Trade  (currently known as Shanghai University of International Business and Economics ) in July 2008, and a Finance MBA from China Europe International Business School (中歐國際工商學院) in November 2022, both in the PRC. He was accredited as a non-practicing Certified Public Accountant by Shanghai Institute of Certified Public Accountants (上海市註冊會計師協會) in December 2015.

Dr. Haiqing Hua has rich experience in the field of drug discovery and development in both multi-national company and domestic pharma company; Primary inventor of multiple novel peptide, antibody and ADC molecules; Direct contribution to IND/NDA approval of biopharmaceuticals in US or China. 

Previously as Head of Biopharmaceuticals and Competitive Intelligence at Hansoh Pharma, leading preclinical discovery and development (nonclinical and CMC), and regulatory affairs of peptide, antibody and ADC programs. 

Previously as Principal Investigator at Eli Lilly, leading drug screening platform, GPCR agonist/antagonist and antibody discovery programs Postdoc in stem cell and gene therapy at Columbia University Medical Center (New York), PhD in neurodegenerative diseases from University of Zurich (Switzerland), and BS from Tsinghua University in China

Mr. CAI Zhiyang, has been appointed as a Director on July 22, 2024 and re-designated as our non-executive Director on August 12, 2024. He is mainly responsible for overseeing Board affairs and providing strategic advice and guidance on the business operations of our Group.

For more than ten years, Mr. CAI has been focusing on the private equity and M&A practices, spearheading investment sourcing, management, consulting and execution. He is the partner of Suzhou Qingtan Private Fund Management Partnership (Limited Partnership), since January 2023. From April 2012 to July 2016, he served at Fountain Investment Consulting (Shanghai) Co., Ltd. with his last position as the vice president of investment, primarily responsible for the evaluation and post-investment management of investment projects. Subsequently, from March 2017 to December 2022, he was a partner at Suzhou Kington Capital Co., Ltd..

Mr. CAI obtained a bachelor’s degree in economics from Fudan University in the PRC in July 2004 and an MBA from the Wharton School of the University of Pennsylvania in the United States in May 2009.

Dr. YU Tao, has been our Director since April 23, 2021 and re-designated as our non-executive Director on August 12, 2024. He is mainly responsible for overseeing Board affairs and providing strategic advice and guidance on the business operations of our Group.

Dr. YU’s career exemplifies the application of strategic ingenuity to the biotechnology sector. He has been serving as managing director at Lilly Asia Ventures, a biomedical venture capital firm focused on healthcare investment, since February 2025, where he also served as principal from March 2018 to February 2025. Dr. YU’s early career, from July 2015 to February 2018, was with McKinsey & Company, where he served as an engagement manager as his last position.

Dr. YU obtained a bachelor’s degree in biological science from Peking University in the PRC in July 2008 and a Ph.D. in biomedical engineering from Johns Hopkins University in the United States in May 2015.

Mr. XIE Dong, has been appointed as an independent non-executive Director with effect from the Listing. He is mainly responsible for providing independent advice and judgment to our Board.

Mr. XIE has nearly 19 years of professional experience in sectors of financial management, auditing, investment and financing, and capital markets. He has served as the (i) chief financial officer and director of QuantaSing Group Limited, a Chinese leading online service provider listed on the Nasdaq (ticker symbol: QSG), since January 2021 and June 2022, respectively; and (ii) independent non-executive director of China BlueChemical Ltd., a state-owned chemical fertilizer producer and leading methanol producer listed on the Stock Exchange (stock code: 3983), since May 2021.

Prior to the above positions, from October 2006 to October 2007, Mr. XIE worked as a staff accountant of the auditing department of Ernst & Young Hua Ming LLP.  From April 2010 to September 2010, he was appointed as vice president of CCB International (China) Limited . From October 2010 to August 2014, he served as associate director at Deloitte China. From September 2014 to December 2018, he served as the chief financial officer and company secretary of FinUp Finance Technology Group (Holding) Limited. From January 2019 to March 2020, he served as the director and chief financial officer of Renmai Technology Group (Holding) Limited .

Mr. XIE obtained a bachelor’s degree in economics and a master’s degree in world economics from Nankai University in June 2003 and June 2006, respectively. He is a holder of Chinese Institute of Certified Public Accountants (CICPA), Certified Internal Auditor (CIA), Certified Tax Agent (CTA) and Chinese Legal Professional Qualification.

Mr. GAO Fengyong,  has been appointed as an independent non-executive Director with effect from the Listing. He is mainly responsible for providing independent advice and judgment to our Board.

Since the nineties, Mr. GAO has been engaged in investment and financing activities. Concurrently outside our Group, Mr. GAO is (i) the founder and director of Shanghai Leading Investment Management Co., Ltd. founder, partner and chairman of the board of Shanghai Blue Ocean Capital Co., Ltd. since September 2012, and (iii) a supervisor of Wuhan Guide Technology Co., Ltd., a company specializing in development, production and sales in industrial automation, since January 2022. In his early career, Mr. GAO worked at Southern Securities Co., Ltd., engaged in underwriting and sponsorship activities, and Bridge Trust Co., Ltd. , an affiliate of SPIC Industry-Finance Holdings Co., Ltd., a company listed on Shenzhen Stock Exchange (stock code: 000958), with his last position being vice president.

Mr. GAO has been holding and held directorships or supervisory roles in the following listed companies:

• a director of Henan BCCY Environmental Energy Co., Ltd, an environmentally-focused technology enterprise listed on Shenzhen Stock Exchange (stock code: 300614), since January 2016;

• an independent director of CNFinance Holdings Limited, a leading home equity loan service provider listed on both the New York Stock Exchange (ticker symbol: CNF), since November 2018;

• an independent director of Nanjing Xinjiekou Department Store Co., Ltd., a company listed on Shanghai Stock Exchange (stock code: 600682), since December 2019;

• a supervisor of Shaanxi Construction Machinery Co., Ltd., a company listed on Shanghai Stock Exchange (stock code: 600984), from October 2015 to November 2017;

• an independent director of China Haisum Engineering Co., Ltd., a comprehensive engineering service company listed on Shenzhen Stock Exchange (stock code: 002116), from August 2016 to May 2023;

• an independent director of Great Wall Movie and Television Co., Ltd., a company previously listed on Shenzhen Stock Exchange (stock code:002071) and delisted in May 2021, from February 2017 to April 2020.

Mr. GAO obtained both his bachelor’s degree and master’s degree in finance from Nankai University in July 1992 and January 2002, respectively

Ms. CHUAI Shuyin, has been appointed as an independent non-executive Director with effect from the Listing. She is mainly responsible for providing independent advice and judgment to our Board.

Ms. CHUAI is the founder of Shanghai Meishen Enterprise Management Consulting Co., Ltd., also known as Mission Consulting , acting as its executive director. From January 2007 to May 2008, she was employed by the Shanghai branch of Zhirui Enterprise Consulting (Shenzhen) Co., Ltd. (currently known as Zhirui Zhuocai Enterprise Consulting (Shanghai) Co., Ltd.. From May 2008 to December 2008, she was recruited by Hewitt Consulting (Shanghai) Co., Ltd. (currently known as Aon Enterprise Services (Shanghai) Co., Ltd.. From March 2009 to April 2010, she worked for Shanghai Maizhi Enterprise Management Consulting Office. Later from December 2011 to April 2016, she was employed by McKinsey & Consulting Company Inc., Shanghai .

Ms. CHUAI obtained a bachelor’s degree in Korean language and culture and a master’s degree in Asian and African languages and literatures from Peking University in July 1998 and June 2001, respectively. She also obtained a master’s degree in art and in human resources and industrial relations from the University of Illinois at Urbana-Champaign in the United States in May 2003 and December 2004, respectively. She is now the honorary president of the Shanghai Alumni Chapter of the University of Illinois Urbana-Champaign.